• Affiliate Professor, Global Health
  • Affiliate Professor, Medicine - Medical Genetics
  • Vice President, IDRI
  • CEO, PAI Life Sciences
  • CEO, Compliment Corp.

Seattle, WA 98102
United States

Phone Number: 
206-714-2724
Fax: 
Select from the following:
Biography 

Darrick Carter is a biochemist/biophysicist with over
20 years of biotech experience. He founded five companies beginning with an internet startup. At Corixa Corp., he led a new tuberculosis vaccine into human trials. He started Protein AI, a bioinformatics company using proprietary artificial neural nets. He helped spin out Dharma Therapeutics a specialty pharma company for drug delivery. Next, he co-founded a company improving cancer outcomes, Compliment Corp. He is inventor on over 120 patents and applications and CEO of PAI Life Sciences as well as being CSO of HDT Bio Corp.

Education 
  • PhD (Oregon Health & Science University)
  • BS (Oregon State University)
Languages 
  • German
Health Topics 
  • Biodefense Infectious Diseases
  • Cancer
  • Cervical Cancer
  • Drug and Vaccine Development
  • Ebola
  • Hepatitis
  • HIV/AIDS
  • Immunizations
  • Infectious Diseases
  • Infectious Diseases (other than STDs)
  • Influenza
  • Informatics
  • Innate Immunity
  • Leishmaniasis
  • Malaria
  • Molecular Immunology
  • Neglected Diseases, Tropical Medicine (incl. Parasites)
  • TB
  • Viruses
Publications 

Erasmus JH, Khandhar AP, O’Connor MA, Walls AC, Hemann EA, Murapa P, Archer J, Leventhal S, Fuller JT, Lewis TB, Draves KE, Randall S, Guerriero KA, Duthie MS, Carter D, Reed SG, Hawman DW, Feldmann H, Gale M, Veesler D, Berglund P, Heydenburg Fuller D. An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Science translational medicine. 2020:eabc9396. doi: 10.1126/scitranslmed.abc9396.

Pitner RA, Durham PG, Stewart IE, Reed SG, Cassell GH, Hickey AJ, Carter D. “A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy”. Journal of Pharmaceutical Sciences, 2019. 108(10), 3302–3311. https://doi.org/10.1016/j.xphs.2019.05.024.

Carter D, van Hoeven N, Baldwin S, Levin Y, Kochba E, Magill A, Charland N, Landry N, Nu K, Frevol A, Ashman J, Sagawa ZK, Beckmann AM, Reed SG. The adjuvant GLA-AF enhances human intradermal vaccine responses. Science - Advances. 2018;4(9). doi: 10.1126/sciadv.aas9930.

Cookenham T, Lanzer KG, Gage E, Lorenzo EC, Carter D, Coler RN, Baldwin SL, Haynes L, Reiley WW, Blackman MA. Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity. Vaccine. 2020. doi: https://doi.org/10.1016/j.vaccine.2020.05.085.

Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Ireton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG. A structure-function approach to optimizing TLR4 ligands for human vaccines. Nature - Clin Trans Immunol. 2016;5:e108. doi: 10.1038/cti.2016.63.